Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Cancer preventive vaccine used in mouse model of Lynch syndrome

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 15.04.19
Views: 955

Prof Steven Lipkin - Weill Cornell Medical College, New York, USA

Prof Steven Lipkin speaks to ecancer at the 2019 American Association for Cancer Research (AACR) meeting about a study looking at the use of a cancer preventative vaccine to treat Lynch syndrome.

He explains that, in order to try and combat the disease earlier and prevent cancer, a vaccine approach was deduced.

Prof Lipkin reports that as few as four recurrent mutations were able to prevent cancer in mice with Lynch syndrome.

He reveals that a phase Ib trial has been proposed to study the use of a vaccine in Lynch syndrome patients.

Read more about this research here.

Related videos

follow us

CLL Janssen

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation